Targeted Medical Pharma, focused on the development and distribution of prescription medical foods to physicians and pharmacies, has unveiled new results from an open label study of the biopharma company's oral amino acid-based erythrocyte stimulating system (NYSE:ESS) for the treatment of chronic anemia.
Subjects in the study were administered 1800mg of ESS daily for seven days, followed by weekly blood sampling for four weeks from the initial dosing, as well as once more 45 days after the initial dose.
Study results demonstrate that hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days; the average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01). Preliminary results of the study released last year showed a 16 percent increase in hemoglobin and a 450 percent increase in peripheral reticulocytes over a seven day period (p<0.01) among normal volunteers taking ESS, which is designed to stimulate progenitor stem cells in the bone marrow.
William Shell, M.D., CEO of TRGM, said the study results are a company landmark showing ESS as the first progenitor of its type to demonstrate such results.
"This is the first demonstration that an oral stimulation of progenitor red blood cells with a targeted amino acid therapy can initiate progenitor stem cell conversion of undifferentiated red blood cells to mature red blood cells with an increase in hemoglobin content in patients with chronic anemia," Dr. Shell stated in the press release. "Developing an oral system for stimulating mature blood cells from progenitor cells is a milestone for our company and may represent a method to modulate red blood cell function in patients with anemia."
TRGM intends to continue testing of the ESS system and to explore additional treatment applications in other forms of anemia.
For more information, visit targetedmedicalpharma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net